» Articles » PMID: 18033313

Myostatin Antisense RNA-mediated Muscle Growth in Normal and Cancer Cachexia Mice

Overview
Journal Gene Ther
Date 2007 Nov 23
PMID 18033313
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

Myostatin is a negative regulator of myogenesis, and inactivation of myostatin leads to muscle growth. Here we have used modified RNA oligonucleotides targeting the myostatin mRNA and examined the therapeutic potential in normal and cancer cachexia mouse models. We found that the RNA oligonucleotides could suppress the myostatin expression in vivo, leading to the increase in muscle growth both in normal and cachectic mice. We also established that the effect of myostatin inhibition caused by the RNA oligonucleotides may be through the MyoD pathway, as evidenced by a significant upregulation of MyoD expression. Taken together, these results demonstrate the feasibility using antisense strategy for the treatment of muscle wasting conditions.

Citing Articles

Oligonucleotide therapeutics in sports? An antidoping perspective.

Parr M, Keiler A Arch Pharm (Weinheim). 2024; 358(1):e2400404.

PMID: 39449227 PMC: 11704058. DOI: 10.1002/ardp.202400404.


Targeting Molecular Mechanisms of Obesity- and Type 2 Diabetes Mellitus-Induced Skeletal Muscle Atrophy with Nerve Growth Factor.

Jun L, Ding X, Robinson M, Jafari H, Knight E, Geetha T Int J Mol Sci. 2024; 25(8).

PMID: 38673892 PMC: 11050157. DOI: 10.3390/ijms25084307.


Highlighting the idea of exerkines in the management of cancer patients with cachexia: novel insights and a critical review.

Ahmadi Hekmatikar A, Nelson A, Petersen A BMC Cancer. 2023; 23(1):889.

PMID: 37730552 PMC: 10512651. DOI: 10.1186/s12885-023-11391-3.


Red blood cell extracellular vesicles deliver therapeutic siRNAs to skeletal muscles for treatment of cancer cachexia.

Peng B, Yang Y, Wu Z, Tan R, Pham T, Yeo E Mol Ther. 2023; 31(5):1418-1436.

PMID: 37016578 PMC: 10188904. DOI: 10.1016/j.ymthe.2023.03.036.


Oligonucleotide Therapeutics for Age-Related Musculoskeletal Disorders: Successes and Challenges.

Nicholson T, Sagmeister M, Wijesinghe S, Farah H, Hardy R, Jones S Pharmaceutics. 2023; 15(1).

PMID: 36678864 PMC: 9866666. DOI: 10.3390/pharmaceutics15010237.